News & Updates

Show Multimedia Only
Multimodal strategies needed to halt progression of MCI and Alzheimer’s disease
Multimodal strategies needed to halt progression of MCI and Alzheimer’s disease
a day ago
Donanemab delays Alzheimer's disease progression over 3 years
Donanemab delays Alzheimer's disease progression over 3 years
a day ago byKanas Chan

Donanemab administered for a limited duration continues to slow clinical progression in patients with early symptomatic Alzheimer’s disease (AD) over 3 years, according to Professor Chaur-Jong Hu of the Department of Neurology, Taipei Medical University, who spoke at Advances in Medicine (AIM) 2026. 

Donanemab delays Alzheimer's disease progression over 3 years
a day ago